vs
Amerant Bancorp Inc.（AMTB）与Apellis Pharmaceuticals, Inc.（APLS）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是Amerant Bancorp Inc.的1.8倍（$199.9M vs $112.2M），Amerant Bancorp Inc.净利率更高（3.0% vs -29.5%，领先32.5%），Amerant Bancorp Inc.同比增速更快（2.9% vs -5.9%），Amerant Bancorp Inc.自由现金流更多（$129.2M vs $-14.3M），过去两年Amerant Bancorp Inc.的营收复合增速更高（10.1% vs 7.7%）
阿梅兰特银行是一家注册于美国佛罗里达州的本土银行，总部坐落于佛罗里达州科勒尔盖布尔斯。目前该行在佛罗里达州共设有19家实体分行，通过自有运营及合作网络可提供超过5.5万台ATM的取款服务。
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
AMTB vs APLS — 直观对比
营收规模更大
APLS
是对方的1.8倍
$112.2M
营收增速更快
AMTB
高出8.8%
-5.9%
净利率更高
AMTB
高出32.5%
-29.5%
自由现金流更多
AMTB
多$143.5M
$-14.3M
两年增速更快
AMTB
近两年复合增速
7.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $112.2M | $199.9M |
| 净利润 | $2.7M | $-59.0M |
| 毛利率 | — | — |
| 营业利润率 | 1.7% | -25.6% |
| 净利率 | 3.0% | -29.5% |
| 营收同比 | 2.9% | -5.9% |
| 净利润同比 | -84.0% | -62.2% |
| 每股收益（稀释后） | $0.08 | $-0.40 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMTBAPLS
| Q4 25 | $112.2M | $199.9M | ||
| Q3 25 | $111.4M | $458.6M | ||
| Q2 25 | $110.3M | $178.5M | ||
| Q1 25 | $105.4M | $166.8M | ||
| Q4 24 | $87.6M | $212.5M | ||
| Q3 24 | $33.3M | $196.8M | ||
| Q2 24 | $98.8M | $199.7M | ||
| Q1 24 | $92.5M | $172.3M |
净利润AMTBAPLS
| Q4 25 | $2.7M | $-59.0M | ||
| Q3 25 | $14.8M | $215.7M | ||
| Q2 25 | $23.0M | $-42.2M | ||
| Q1 25 | $12.0M | $-92.2M | ||
| Q4 24 | $16.9M | $-36.4M | ||
| Q3 24 | $-48.2M | $-57.4M | ||
| Q2 24 | $5.0M | $-37.7M | ||
| Q1 24 | $10.6M | $-66.4M |
营业利润率AMTBAPLS
| Q4 25 | 1.7% | -25.6% | ||
| Q3 25 | 17.1% | 48.7% | ||
| Q2 25 | 27.0% | -18.6% | ||
| Q1 25 | 14.6% | -50.0% | ||
| Q4 24 | 20.6% | -12.3% | ||
| Q3 24 | -185.8% | -24.0% | ||
| Q2 24 | 6.4% | -14.7% | ||
| Q1 24 | 14.6% | -36.0% |
净利率AMTBAPLS
| Q4 25 | 3.0% | -29.5% | ||
| Q3 25 | 13.2% | 47.0% | ||
| Q2 25 | 20.9% | -23.6% | ||
| Q1 25 | 11.3% | -55.3% | ||
| Q4 24 | 19.3% | -17.1% | ||
| Q3 24 | -144.6% | -29.2% | ||
| Q2 24 | 5.0% | -18.9% | ||
| Q1 24 | 11.4% | -38.5% |
每股收益（稀释后）AMTBAPLS
| Q4 25 | $0.08 | $-0.40 | ||
| Q3 25 | $0.35 | $1.67 | ||
| Q2 25 | $0.55 | $-0.33 | ||
| Q1 25 | $0.28 | $-0.74 | ||
| Q4 24 | $0.53 | $-0.30 | ||
| Q3 24 | $-1.43 | $-0.46 | ||
| Q2 24 | $0.15 | $-0.30 | ||
| Q1 24 | $0.31 | $-0.54 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $466.2M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $938.8M | $370.1M |
| 总资产 | $9.8B | $1.1B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资AMTBAPLS
| Q4 25 | — | $466.2M | ||
| Q3 25 | — | $479.2M | ||
| Q2 25 | — | $370.0M | ||
| Q1 25 | — | $358.4M | ||
| Q4 24 | — | $411.3M | ||
| Q3 24 | — | $396.9M | ||
| Q2 24 | — | $360.1M | ||
| Q1 24 | — | $325.9M |
总债务AMTBAPLS
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $93.1M |
股东权益AMTBAPLS
| Q4 25 | $938.8M | $370.1M | ||
| Q3 25 | $944.9M | $401.2M | ||
| Q2 25 | $924.3M | $156.3M | ||
| Q1 25 | $906.3M | $164.2M | ||
| Q4 24 | $890.5M | $228.5M | ||
| Q3 24 | $902.9M | $237.1M | ||
| Q2 24 | $734.3M | $264.3M | ||
| Q1 24 | $738.1M | $266.7M |
总资产AMTBAPLS
| Q4 25 | $9.8B | $1.1B | ||
| Q3 25 | $10.4B | $1.1B | ||
| Q2 25 | $10.3B | $821.4M | ||
| Q1 25 | $10.2B | $807.3M | ||
| Q4 24 | $9.9B | $885.1M | ||
| Q3 24 | $10.4B | $901.9M | ||
| Q2 24 | $9.7B | $904.5M | ||
| Q1 24 | $9.8B | $831.9M |
负债/权益比AMTBAPLS
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 0.35× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $137.0M | $-14.2M |
| 自由现金流经营现金流 - 资本支出 | $129.2M | $-14.3M |
| 自由现金流率自由现金流/营收 | 115.2% | -7.1% |
| 资本支出强度资本支出/营收 | 6.9% | 0.1% |
| 现金转化率经营现金流/净利润 | 50.71× | — |
| 过去12个月自由现金流最近4个季度 | $225.2M | $45.0M |
8季度趋势，按日历期对齐
经营现金流AMTBAPLS
| Q4 25 | $137.0M | $-14.2M | ||
| Q3 25 | $22.7M | $108.5M | ||
| Q2 25 | $57.6M | $4.4M | ||
| Q1 25 | $20.2M | $-53.4M | ||
| Q4 24 | $82.2M | $19.4M | ||
| Q3 24 | $4.2M | $34.1M | ||
| Q2 24 | $-2.3M | $-8.3M | ||
| Q1 24 | $2.8M | $-133.0M |
自由现金流AMTBAPLS
| Q4 25 | $129.2M | $-14.3M | ||
| Q3 25 | $21.7M | $108.3M | ||
| Q2 25 | $56.3M | $4.4M | ||
| Q1 25 | $18.0M | $-53.4M | ||
| Q4 24 | $74.8M | $19.3M | ||
| Q3 24 | $2.6M | — | ||
| Q2 24 | $-3.9M | $-8.4M | ||
| Q1 24 | $-694.0K | $-133.3M |
自由现金流率AMTBAPLS
| Q4 25 | 115.2% | -7.1% | ||
| Q3 25 | 19.5% | 23.6% | ||
| Q2 25 | 51.0% | 2.5% | ||
| Q1 25 | 17.1% | -32.0% | ||
| Q4 24 | 85.3% | 9.1% | ||
| Q3 24 | 7.8% | — | ||
| Q2 24 | -3.9% | -4.2% | ||
| Q1 24 | -0.8% | -77.3% |
资本支出强度AMTBAPLS
| Q4 25 | 6.9% | 0.1% | ||
| Q3 25 | 0.9% | 0.0% | ||
| Q2 25 | 1.2% | 0.0% | ||
| Q1 25 | 2.1% | 0.0% | ||
| Q4 24 | 8.4% | 0.0% | ||
| Q3 24 | 4.8% | 0.0% | ||
| Q2 24 | 1.5% | 0.0% | ||
| Q1 24 | 3.8% | 0.2% |
现金转化率AMTBAPLS
| Q4 25 | 50.71× | — | ||
| Q3 25 | 1.54× | 0.50× | ||
| Q2 25 | 2.50× | — | ||
| Q1 25 | 1.69× | — | ||
| Q4 24 | 4.87× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -0.47× | — | ||
| Q1 24 | 0.26× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMTB
| Other | $58.0M | 52% |
| Commercial Portfolio Segment | $25.7M | 23% |
| Commercial Real Estate Portfolio Segment | $17.3M | 15% |
| Consumer Portfolio Segment | $11.1M | 10% |
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
